The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 01, 2020
Filed:
Aug. 16, 2017
Applicant:
Novartis Ag, Basel, CH;
Inventors:
Florian Karl Kleinbeck-Riniker, Zurich, CH;
Ives Mafli, Zurich, CH;
Benjamin Martin, Leymen, FR;
Gerhard Penn, Oberwil, CH;
Gottfried Sedelmeier, Schallstadt, DE;
Joerg Sedelmeier, Weil am Rhein, DE;
Francesco Venturoni, Saint-Louis, FR;
Assignee:
Novartis AG, Basel, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 271/22 (2006.01); C07D 213/16 (2006.01); C07C 201/12 (2006.01); C07C 251/38 (2006.01); C07C 201/16 (2006.01); C07C 205/53 (2006.01); C07C 249/08 (2006.01); C07D 213/36 (2006.01); C07C 205/51 (2006.01); C07C 67/347 (2006.01); C07C 231/02 (2006.01); C07C 269/00 (2006.01); C07C 201/06 (2006.01); C07C 227/18 (2006.01); C07C 45/49 (2006.01); C07C 229/06 (2006.01); C07C 249/02 (2006.01); C07D 207/267 (2006.01); C07D 207/12 (2006.01);
U.S. Cl.
CPC ...
C07D 213/16 (2013.01); C07C 45/49 (2013.01); C07C 67/347 (2013.01); C07C 201/06 (2013.01); C07C 201/12 (2013.01); C07C 201/16 (2013.01); C07C 205/51 (2013.01); C07C 205/53 (2013.01); C07C 227/18 (2013.01); C07C 229/06 (2013.01); C07C 231/02 (2013.01); C07C 249/02 (2013.01); C07C 249/08 (2013.01); C07C 251/38 (2013.01); C07C 269/00 (2013.01); C07C 271/22 (2013.01); C07D 207/267 (2013.01); C07D 213/36 (2013.01); C07B 2200/07 (2013.01); C07D 207/12 (2013.01);
Abstract
The present invention relates to a new chemical synthesis, intermediates and catalysts useful for the preparation of the neprilysin (NEP) inhibitor sacubitril, inter alia via nitro 5 compounds. It further relates to new intermediate compounds and their use for said new chemical synthesis route, as well as a new catalyst ligand.